argenx SE (ARGX)
NASDAQ: ARGX · Real-Time Price · USD
846.27
+27.97 (3.42%)
At close: Oct 15, 2026, 4:00 PM EDT
856.84
+10.57 (1.25%)
After-hours: Oct 15, 2026, 4:51 PM EDT
argenx SE Revenue
argenx SE had revenue of $1.54B in the quarter ending June 30, 2026, with 59.30% growth. This brings the company's revenue in the last twelve months to $5.33B, up 70.59% year-over-year. In the year 2025, argenx SE had annual revenue of $4.25B with 88.63% growth.
Revenue (ttm)
$5.33B
Revenue Growth
+70.59%
P/S Ratio
9.76
Revenue / Employee
$2,853,177
Employees
1,863
Market Cap
53.68B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.25B | 2.00B | 88.63% |
| Dec 31, 2024 | 2.25B | 983.45M | 77.52% |
| Dec 31, 2023 | 1.27B | 823.33M | 184.91% |
| Dec 31, 2022 | 445.27M | -94.15M | -17.45% |
| Dec 31, 2021 | 539.42M | 474.51M | 731.01% |
| Dec 31, 2020 | 64.91M | -29.11M | -30.96% |
| Dec 31, 2019 | 94.03M | 60.43M | 179.91% |
| Dec 31, 2018 | 33.59M | -15.91M | -32.14% |
| Dec 31, 2017 | 49.50M | 31.46M | 174.30% |
| Dec 31, 2016 | 18.05M | 7.24M | 66.96% |
| Dec 31, 2015 | 10.81M | 4.30M | 66.15% |
| Dec 31, 2014 | 6.51M | -719.25K | -9.95% |
| Dec 31, 2013 | 7.23M | 3.23M | 80.71% |
| Dec 31, 2012 | 4.00M | 9.75K | 0.24% |
| Dec 31, 2011 | 3.99M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Regeneron Pharmaceuticals | 15.53B |
| BeOne Medicines AG | 6.13B |
| Incyte | 5.82B |
| Alnylam Pharmaceuticals | 4.80B |
| Genmab | 4.13B |
| BioNTech SE | 3.03B |
| Royalty Pharma | 2.54B |
| Moderna | 2.23B |
ARGX News
- 16 hours ago - argenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026 - GlobeNewsWire
- 1 day ago - ARGX Maintained by Wells Fargo -- Price Target Raised to $1356 - GuruFocus
- 1 day ago - Argenx price target raised to $1,356 from $1,355 at Wells Fargo - TheFly
- 3 days ago - ARGX Investors with $100,000 in Losses Have Opportunity to Join argenx SE Fraud Investigation with SBS Law - Business Wire
- 3 days ago - ARGX Maintains by Oppenheimer -- Price Target Lowered to $1038 - GuruFocus
- 3 days ago - Argenx price target lowered to $1,038 from $1,100 at Oppenheimer - TheFly
- 3 days ago - Argenx price target raised to $1,157 from $1,136 at BofA - TheFly
- 6 days ago - ARGX Maintains Rating by Evercore ISI Group -- Price Target Lowers to $1078 - GuruFocus